Factors influencing magnitude and duration of target inhibition following antibody therapy: Implications in drug discovery and development

AAPS Journal

Volumn 15, Issue 3, 2013, Pages 717-727

  Chimalakonda, Anjaneya P ^a   Yadav, Rajbharan ^b   Marathe, Punit ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b SYNGENE INTERNATIONAL LTD   (India)

Author keywords

antibody; drug discovery; lead optimization; PK PD; TMDD

Indexed keywords

MONOCLONAL ANTIBODY; OMALIZUMAB;

ARTICLE; BINDING AFFINITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; MATHEMATICAL MODEL; SIMULATION; TARGET MEDIATED DRUG DISPOSITION MODEL; THEORETICAL STUDY;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; MODELS, IMMUNOLOGICAL; PROTEIN BINDING;

EID: 84879799986     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9477-3     Document Type: Article

References (29)

1. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 2008;9(6):423-30.
2. Reichert JM. Metrics for antibody therapeutics development. MAbs. 2010;2(6):695-700.
3. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325-38.
4. Munro TP, Mahler SM, Huang EP, Chin DY, Gray PP. Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates. MAbs. 2011;3(5):440-52.
5. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58.
6. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63(5):548-61.
7. Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793-807.
8. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol. 2005;96(3):182-92.
9. Ait-Oudhia S, Lowe PJ, Mager DE. Bridging clinical outcomes of canakinumab treatment in patients with rheumatoid arthritis with a population model of IL-1[beta] kinetics. CPT: Pharmacomet Syst Pharmacol. 2012;1:e5.
10. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72(1):1-10.
11. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-32.
12. Tang C, Prueksaritanont T. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target. Pharm Res. 2011;28(10):2447-57.
13. Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs. 2010;2(5):576-88.
14. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today. 2007;12(23-24):1018-24.
15. Agoram BM, Martin SW, Van der Graaf PH. Application of mechanism-based population PKPD modelling in the rational selection of clinical candidates: an anti-IgE antibody example. Population Approach Group in Europe; København, Denmark 2007.
16. Lowe PJ. Applying physiological and biochemical concepts to optimize biological drug development. Clin Pharmacol Ther. 2010;87(4):492-6.
17. Yu J, Karcher H, Feire AL, Lowe PJ. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J. 2011;13(2):169-78.
18. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009;5(7):803-12.
19. Aston PJ, Derks G, Raji A, Agoram BM, van der Graaf PH. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol. 2011;281(1):113-21.
20. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17(9-10):419-24.
21. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008;10(2):425-30.
22. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-68.
23. Perchiacca JM, Tessier PM. Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng. 2012;3:263-86.
24. Roskos L, Klakamp S, Liang M, Arends R, Green L. Molecular engineering II: antibody affinity. In: Dubel S, editor. Handbook of therapeutic antibodies. Weinheim: Wiley; 2007. p. 145-69.
25. Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J. 2012;14(4):850-9.
26. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol. 2006;176(1):346-56.
27. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28(11):1203-7.
28. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012;287(14):11090-7.
29. Kuester K, Kloft C. Pharmacokinetics of monoclonal antibodies. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. Weinheim: Wiley; 2006. p. 45-92.